Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 3 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Development of a quantitative ELISA for SARS-CoV-2 vaccine candidate, NDV-HXP-S, with CpG 1018® adjuvant.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2315709. doi: 10.1080/21645515.2024.2315709. Epub 2024 Feb 19.
Hum Vaccin Immunother. 2024.
PMID: 38372198
Free PMC article.
Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination.
Costa PR, Correia CA, Marmorato MP, de Carvalho Dias JZ, Thomazella MV, da Silva AC, de Oliveira ACS, Gusmão AF, Ferrari L, Freitas AC, Patiño EG, Grifoni A, Weiskopf D, Sette A, Scharf R, Kallas EG, Terrassani Silveira CG.
Costa PR, et al.
medRxiv [Preprint]. 2022 Jul 7:2022.03.16.22272513. doi: 10.1101/2022.03.16.22272513.
medRxiv. 2022.
PMID: 35821982
Free PMC article.
Updated.
Preprint.
Item in Clipboard
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
Duc Dang A, Dinh Vu T, Hai Vu H, Thanh Ta V, Thi Van Pham A, Thi Ngoc Dang M, Van Le B, Huu Duong T, Van Nguyen D, Lawpoolsri S, Chinwangso P, McLellan JS, Hsieh CL, Garcia-Sastre A, Palese P, Sun W, Martinez JL, Gonzalez-Dominguez I, Slamanig S, Manuel Carreño J, Tcheou J, Krammer F, Raskin A, Minh Vu H, Cong Tran T, Mai Nguyen H, Mercer LD, Raghunandan R, Lal M, White JA, Hjorth R, Innis BL, Scharf R.
Duc Dang A, et al.
Vaccine. 2022 Jun 9;40(26):3621-3632. doi: 10.1016/j.vaccine.2022.04.078. Epub 2022 May 14.
Vaccine. 2022.
PMID: 35577631
Free PMC article.
Clinical Trial.
Item in Clipboard
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.
Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, Narakorn P, Surichan S, Prangpratanporn S, Puksuriwong S, Lamola S, Mercer LD, Raghunandan R, Sun W, Liu Y, Carreño JM, Scharf R, Phumratanaprapin W, Amanat F, Gagnon L, Hsieh CL, Kaweepornpoj R, Khan S, Lal M, McCroskery S, McLellan J, Mena I, Meseck M, Phonrat B, Sabmee Y, Singchareon R, Slamanig S, Suthepakul N, Tcheou J, Thantamnu N, Theerasurakarn S, Tran S, Vilasmongkolchai T, White JA, Bhardwaj N, Garcia-Sastre A, Palese P, Krammer F, Poopipatpol K, Wirachwong P, Hjorth R, Innis BL.
Pitisuttithum P, et al.
EClinicalMedicine. 2022 Mar 8;45:101323. doi: 10.1016/j.eclinm.2022.101323. eCollection 2022 Mar.
EClinicalMedicine. 2022.
PMID: 35284808
Free PMC article.
Item in Clipboard
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.
Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamanig S, Coughlan L, Rosado V, Lemus N, Jangra S, Rathnasinghe R, Schotsaert M, Martinez JL, Sano K, Mena I, Innis BL, Wirachwong P, Thai DH, Oliveira RDN, Scharf R, Hjorth R, Raghunandan R, Krammer F, García-Sastre A, Palese P.
Sun W, et al.
Nat Commun. 2021 Oct 27;12(1):6197. doi: 10.1038/s41467-021-26499-y.
Nat Commun. 2021.
PMID: 34707161
Free PMC article.
Item in Clipboard
Cite
Cite